Drug Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Drug Name Enfortumab vedotin-ejfv
Trade Name Padcev
Synonyms AGS-22ME|Enfortumab vedotin|AGS-22M6E|ASG-22CE
Drug Descriptions

Padcev (enfortumab vedotin-ejfv) is an antibody-drug conjugate (ADC) that fuses together a human antibody against NECTIN4 and monomethyl auristatin E, which may result in inhibition of tumor growth and tumor regression (PMID: 27013195). Padcev (enfortumab vedotin-ejfv) is FDA approved for use in patients with locally advanced or metastatic urothelial cancer who have previously received a PD-1 or PD-L1 inhibitor, and a platinum-containing chemotherapy, or who are ineligible for cisplatin-containing chemotherapy and have previously received one or more prior lines of therapy, and in combination with Keytruda (pembrolizumab) for patients with locally advanced or metastatic urothelial carcinoma ineligible for cisplatin-containing chemotherapy (FDA.gov).

DrugClasses
CAS Registry Number 1346452-25-2
NCIT ID C114500

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Therapy Name Drugs Efficacy Evidence Clinical Trials
Atezolizumab + Enfortumab vedotin-ejfv Atezolizumab Enfortumab vedotin-ejfv 0 1
Atezolizumab + Enfortumab vedotin-ejfv + Pembrolizumab Atezolizumab Enfortumab vedotin-ejfv Pembrolizumab 0 1
Cabozantinib + Enfortumab vedotin-ejfv Cabozantinib Enfortumab vedotin-ejfv 0 1
Carboplatin + Enfortumab vedotin-ejfv + Pembrolizumab Carboplatin Enfortumab vedotin-ejfv Pembrolizumab 0 1
Cisplatin + Enfortumab vedotin-ejfv + Pembrolizumab Cisplatin Enfortumab vedotin-ejfv Pembrolizumab 0 1
Durvalumab + Enfortumab vedotin-ejfv Durvalumab Enfortumab vedotin-ejfv 0 0
Durvalumab + Enfortumab vedotin-ejfv + Tremelimumab Durvalumab Enfortumab vedotin-ejfv Tremelimumab 0 1
Enfortumab vedotin-ejfv Enfortumab vedotin-ejfv 0 12
Enfortumab vedotin-ejfv + Erdafitinib Enfortumab vedotin-ejfv Erdafitinib 0 1
Enfortumab vedotin-ejfv + Evorpacept Enfortumab vedotin-ejfv Evorpacept 0 1
Enfortumab vedotin-ejfv + MK-4280A Enfortumab vedotin-ejfv MK-4280A 0 1
Enfortumab vedotin-ejfv + MK-7684A Enfortumab vedotin-ejfv MK-7684A 0 1
Enfortumab vedotin-ejfv + Pembrolizumab Enfortumab vedotin-ejfv Pembrolizumab 0 11
Enfortumab vedotin-ejfv + Sacituzumab govitecan-hziy Enfortumab vedotin-ejfv Sacituzumab govitecan-hziy 0 1
Enfortumab vedotin-ejfv + Sitravatinib Enfortumab vedotin-ejfv Sitravatinib 0 1


Additional content available in CKB BOOST